Evidence map›Paper›PMID 25302950›Full record

ArticlePloS one2014

A new ochratoxin A biodegradation strategy using Cupriavidus basilensis Őr16 strain.

Szilamér Ferenczi, Mátyás Cserháti, Csilla Krifaton, Sándor Szoboszlay, József Kukolya, Zsuzsanna Szőke, Balázs Kőszegi, Mihály Albert, Teréz Barna, Miklós Mézes and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Efficient degradation of neomycin byFrontiers in microbiology · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Evaluation of the Safety and Ochratoxin A Degradation Capacity ofInternational journal of molecular sciences · 2022
    Article
  12. Review
  13. Review
  14. International journal of molecular sciences · 2021
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Szilamér FerencziInstitute of Experimental Medicine, Laboratory of Molecular Neuroendocrinology, Budapest, Hungary.
Mátyás CserhátiSzent István University, Department of Environmental Protection and Safety, Gödöllő, Hungary.
Csilla KrifatonSzent István University, Department of Environmental Protection and Safety, Gödöllő, Hungary.
Sándor SzoboszlaySzent István University, Department of Environmental Protection and Safety, Gödöllő, Hungary.
József KukolyaCentral Environmental and Food Science Research Institute, Department of Microbiology, Budapest, Hungary.
Zsuzsanna SzőkeSoft Flow Hungary R&D Ltd., Pécs, Hungary.
Balázs KőszegiSoft Flow Hungary R&D Ltd., Pécs, Hungary.
Mihály AlbertCEVA Phylaxia Ltd, Budapest, Hungary.
Teréz BarnaUniversity of Debrecen, Department of Genetics and Applied Microbiology, Debrecen, Hungary.
Miklós MézesSzent István University, Department of Nutrition, Gödöllő, Hungary.
Krisztina J KovácsInstitute of Experimental Medicine, Laboratory of Molecular Neuroendocrinology, Budapest, Hungary.
Balázs KrisztSzent István University, Department of Environmental Protection and Safety, Gödöllő, Hungary.
Magyar Agrár- és Élettudományi Egyetem · HU4D Soft (Hungary) · HUHUN-REN Institute of Experimental Medicine · HUCentral Environmental and Food Science Research Institute · HUTeva Pharmaceuticals (Hungary) · HUUniversity of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ochratoxin-A (OTA) is a mycotoxin with possibly carcinogenic and nephrotoxic effects in humans and animals. OTA is often found as a contaminant in agricultural commodities. The aim of the present work was to evaluate OTA-degrading and detoxifying potential of Cupriavidus basilensis ŐR16 strain. In vivo administration of OTA in CD1 male mice (1 or 10 mg/kg body weight for 72 hours or 0.5 mg/kg body weight for 21 days) resulted in significant elevation of OTA levels in the blood, histopathological alterations- and transcriptional changes in OTA-dependent genes (annexinA2, clusterin, sulphotransferase and gadd45 and gadd153) in the renal cortex. These OTA-induced changes were not seen in animals that have been treated with culture supernatants in which OTA was incubated with Cupriavidus basilensis ŐR16 strain for 5 days. HPLC and ELISA methods identified ochratoxin α as the major metabolite of OTA in Cupriavidus basilensis ŐR16 cultures, which is not toxic in vivo. This study has demonstrated that Cupriavidus basilensis ŐR16 efficiently degrade OTA without producing toxic adventitious metabolites.

Indexed as

Biodegradation, EnvironmentalAnimalsCarcinogensCupriavidusKidneyMaleMiceMycotoxinsOchratoxinsCarcinogensMycotoxinsochratoxin AOchratoxins

Identifiers

PMID25302950
PMCPMC4193827
OpenAlexW2100994231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.